Table 1.
Clinical parameters measured at 16 weeks after treatment with MMF or Valsartan
| Groups (n=8) | NC | DN | DN + M | DN + V |
|---|---|---|---|---|
| Kw/Bw (‰) | 4.57±0.24 | 8.49±0.43** | 5.86±0.25*,# | 6.25±0.37**,# |
| Blood glucose (mg/dl) | 108.1±2.3 | 328.7±4.54** | 323.4±3.36** | 335.9±4.78** |
| Serum creatinine (mg/dL) | 0.96±0.02 | 0.97±0.05 | 0.93±0.04 | 0.99±0.03 |
| urinary protein (mg/24 h) | 16.52±0.66 | 55.37±2.33** | 23.84±1.83*,# | 29.10±1.27**,# |
MMF: mycophenolate mofetil; NC: normal control; DN: dissolvent (DM); DM + M: 15 mg/kg/d of MMF; DM + V: Valsartan. Data are shown as mean ± SEM.
*
P<0.05 vs NC group;
**
P<0.01 vs NC group.
#
P<0.01 indicates the significant difference as compared with DN group.